CITI/CALL/GILEAD SCIENCES/95/0.1/20.06.24 | Market Closed - Deutsche Boerse AG 13:40:06 2024-05-17 EDT | ||
| 0.001 EUR | 0.00% |
|
| Current year | -98.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-17 | 0.001 | 0.00% |
| 24-05-16 | 0.001 | 0.00% |
| 24-05-15 | 0.001 | 0.00% |
| 24-05-14 | 0.001 | 0.00% |
| 24-05-13 | 0.001 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 01:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Citi
|
| WKN | KG57CA |
| ISIN | DE000KG57CA7 |
| Date issued | 2022-07-05 |
| Strike | 95 $ |
| Maturity | 2024-06-20 (34 Days) |
| Parity | 10 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.95 € |
|---|---|
| Lowest since issue | 0.001 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.72
USD
Average target price
82.93
USD
Spread / Average Target
+22.46%
- Stock Market
- Warrants
- Warrant
